
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Melanoma is rare among pediatric patients, but it does occur. And the best way to determine whether to excise a lesion on a young patient is by using dermoscopy, according to Robert Johr, M.D., a dermatologist who practices in Boca Raton, Fla.